These biopharma stocks are taking a big hit because of the COVID-19 pandemic.
News & Analysis: BioMarin Pharmaceutical
An overall market rebound and a presidential press conference carried several biotech and pharmaceutical stocks markedly higher.
BioMarin's stock isn't escaping the marketwide sell-off. Savvy investors, though, may want to take advantage of this latest decline in the drugmaker's shares.
Even healthcare companies can't escape the overall market downturn.
BMRN earnings call for the period ending December 31, 2019.
The gene therapy maker's novel medicine has the potential to take over a highly competitive market and offer growth opportunities for investors.
The agency expects to make a decision by Aug. 21, 2020.
The company is developing a novel enzyme-based treatment for phenylketonuria (PKU), but it faces growing competition from potentially curative gene therapies.
These stocks could thump the broader markets this year.
If approved, Valrox could become the most expensive drug in the world.